Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes.

[1]  W. Prichard,et al.  A new class of uncoupling agents--carbonyl cyanide phenylhydrazones. , 1962, Biochemical and biophysical research communications.

[2]  P. Workman,et al.  DT-diaphorase and cancer chemotherapy. , 1992, Biochemical pharmacology.

[3]  M. Pirmohamed,et al.  Idiosyncratic Drug Reactions , 1996 .

[4]  A. Guillouzo,et al.  Liver cell models in in vitro toxicology. , 1998, Environmental health perspectives.

[5]  Kathy Carroll,et al.  Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.

[6]  G. Hamilton,et al.  Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions , 2001, Cell and Tissue Research.

[7]  A. Li,et al.  Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[8]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Frank Stahl,et al.  Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[10]  U. Preuss,et al.  Novel mitosis-specific phosphorylation of histone H3 at Thr11 mediated by Dlk/ZIP kinase. , 2003, Nucleic acids research.

[11]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[12]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[13]  M. Monshouwer,et al.  An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. , 2005, Toxicology.

[14]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[15]  S. Hansen,et al.  Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity , 2007, Cell Biology and Toxicology.

[16]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  R. Riley,et al.  Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes , 2008, Drug Metabolism and Disposition.

[18]  J. Uetrecht,et al.  Immunoallergic Drug-Induced Liver Injury in Humans , 2009, Seminars in liver disease.

[19]  Jiri Aubrecht,et al.  Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. , 2010, Toxicology letters.

[20]  S. O. Mueller,et al.  Development of stably transfected human and rat hepatoma cell lines for the species-specific assessment of xenobiotic response enhancer module (XREM)-dependent induction of drug metabolism. , 2010, Toxicology.

[21]  R. Soto-Otero,et al.  Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants. , 2011, Journal of pharmacological and toxicological methods.

[22]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[23]  Yan Li,et al.  Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.

[24]  M. Xia,et al.  Assessment of compound hepatotoxicity using human plateable cryopreserved hepatocytes in a 1536-well-plate format. , 2012, Assay and drug development technologies.

[25]  Yvonne Will,et al.  Evaluation of drugs with specific organ toxicities in organ-specific cell lines. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  Yan Li,et al.  In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.

[27]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[28]  Wonyong Kim,et al.  Combined Effect of Hsp90 Inhibitor Geldanamycin and Parthenolide via Reactive Oxygen Species‐Mediated Apoptotic Process on Epithelial Ovarian Cancer Cells , 2012, Basic & clinical pharmacology & toxicology.

[29]  Johannes Kornhuber,et al.  Identification of Drugs Inducing Phospholipidosis by Novel in vitro Data , 2012, ChemMedChem.

[30]  B. Rigas,et al.  Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans. , 2013, Biochemical pharmacology.

[31]  Matthew H Bridgland-Taylor,et al.  A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.